Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Usman Nakakana

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|October 5, 2023
Outer Membrane Vesicle Vaccine PlatformsFrancesca Micoli, Roberto Adamo, Usman Nakakana
Human Vaccines & Immunotherapeutics|January 12, 2026
<i>Shigella sonnei</i> and <i>Shigella flexneri</i>: Epidemiology supporting development of cross-protective vaccinesValentina Caradonna, Agnes Hunyady, Usman Nakakana, et al.
Human Vaccines & Immunotherapeutics|September 19, 2015
Polio elimination in Nigeria: A reviewUsman Nakakana Nasir, Ananda Sankar Bandyopadhyay, Francesca Montagnani, et al.
Infectious Diseases and Therapy|February 4, 2022
GMMA Technology for the Development of Safe Vaccines: Meta-Analysis of Individual Patient Data to Assess the Safety Profile of Shigella sonnei 1790GAHB Vaccine in Healthy Adults, with Special Focus on NeutropeniaIris De Ryck, Eleanna Sarakinou, Usman Nakakana, et al.
Infectious Diseases and Therapy|April 18, 2022
Correction to: GMMA Technology for the Development of Safe Vaccines: Meta-Analysis of Individual Patient Data to Assess the Safety Profile of Shigella sonnei 1790GAHB Vaccine in Healthy Adults, with Special Focus on NeutropeniaIris De Ryck, Eleanna Sarakinou, Usman Nakakana, et al.
Drugs in R&D|March 18, 2024
Application of Transthoracic Echocardiography for Cardiac Safety Evaluation in the Clinical Development Process of Vaccines Against Streptococcus pyogenesUsman Nakakana, Alimamy Serry-Bangura, Bassey Effiom Edem, et al.
BMJ Open|November 14, 2023
<i>Salmonella</i> Vaccine Study in Oxford (SALVO) trial: protocol for an observer-participant blind randomised placebo-controlled trial of the iNTS-GMMA vaccine within a European cohortBrama Hanumunthadu, Nasir Kanji, Nelly Owino, et al.
Frontiers in Immunology|October 7, 2022
Complement-mediated serum bactericidal activity of antibodies elicited by the <i>Shigella sonnei</i> GMMA vaccine in adults from a shigellosis-endemic country: Exploratory analysis of a Phase 2a randomized studyMelissa C Kapulu, Usman Nakakana, Antonella S Sciré, et al.
NPJ Vaccines|December 13, 2025
Evaluation of cross-functional antibody responses elicited by a four-component GMMA Shigella vaccineValentina Caradonna, Eleanna Sarakinou, Roberta Di Benedetto, et al.
Msphere|April 16, 2025
Protein-specific immune response elicited by the <i>Shigella sonnei</i> 1790GAHB GMMA-based candidate vaccine in adults with varying exposure to <i>Shigella</i>Arlo Z Randall, Valentino Conti, Usman Nakakana, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|October 5, 2023
Outer Membrane Vesicle Vaccine PlatformsFrancesca Micoli, Roberto Adamo, Usman Nakakana
Human Vaccines & Immunotherapeutics|January 12, 2026
<i>Shigella sonnei</i> and <i>Shigella flexneri</i>: Epidemiology supporting development of cross-protective vaccinesValentina Caradonna, Agnes Hunyady, Usman Nakakana, et al.
Human Vaccines & Immunotherapeutics|September 19, 2015
Polio elimination in Nigeria: A reviewUsman Nakakana Nasir, Ananda Sankar Bandyopadhyay, Francesca Montagnani, et al.
Infectious Diseases and Therapy|February 4, 2022
GMMA Technology for the Development of Safe Vaccines: Meta-Analysis of Individual Patient Data to Assess the Safety Profile of Shigella sonnei 1790GAHB Vaccine in Healthy Adults, with Special Focus on NeutropeniaIris De Ryck, Eleanna Sarakinou, Usman Nakakana, et al.
Infectious Diseases and Therapy|April 18, 2022
Correction to: GMMA Technology for the Development of Safe Vaccines: Meta-Analysis of Individual Patient Data to Assess the Safety Profile of Shigella sonnei 1790GAHB Vaccine in Healthy Adults, with Special Focus on NeutropeniaIris De Ryck, Eleanna Sarakinou, Usman Nakakana, et al.
Drugs in R&D|March 18, 2024
Application of Transthoracic Echocardiography for Cardiac Safety Evaluation in the Clinical Development Process of Vaccines Against Streptococcus pyogenesUsman Nakakana, Alimamy Serry-Bangura, Bassey Effiom Edem, et al.
BMJ Open|November 14, 2023
<i>Salmonella</i> Vaccine Study in Oxford (SALVO) trial: protocol for an observer-participant blind randomised placebo-controlled trial of the iNTS-GMMA vaccine within a European cohortBrama Hanumunthadu, Nasir Kanji, Nelly Owino, et al.
Frontiers in Immunology|October 7, 2022
Complement-mediated serum bactericidal activity of antibodies elicited by the <i>Shigella sonnei</i> GMMA vaccine in adults from a shigellosis-endemic country: Exploratory analysis of a Phase 2a randomized studyMelissa C Kapulu, Usman Nakakana, Antonella S Sciré, et al.
NPJ Vaccines|December 13, 2025
Evaluation of cross-functional antibody responses elicited by a four-component GMMA Shigella vaccineValentina Caradonna, Eleanna Sarakinou, Roberta Di Benedetto, et al.
Msphere|April 16, 2025
Protein-specific immune response elicited by the <i>Shigella sonnei</i> 1790GAHB GMMA-based candidate vaccine in adults with varying exposure to <i>Shigella</i>Arlo Z Randall, Valentino Conti, Usman Nakakana, et al.
Pageof 1